Ireland's Amarin Q2 revenue falls on lower licensing payments
AMRN•Outlook
- Amarin expects continued growth in international markets for the remainder of 2026.
- The company expects U.S. VASCEPA volumes to remain consistent throughout FY 2026.
- Amarin expects positive cash flow generation and cash to grow by 10% by year-end 2026.
Result drivers and key details
- Licensing payment impact - Net revenue decline mainly due to the absence of a $25 million upfront payment from Recordati in the prior-year quarter.
- Generic competition - Modest decline in U.S. sales driven by continued generic competition and net pricing pressure, partly offset by higher branded VASCEPA demand.
- Cost savings - Operating expenses fell 59% yr/yr as the company completed a $70 million annual cost savings initiative.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Operating Expenses | $27 mln |
The one available analyst rating on the shares is "sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Quarterly revenue and expense trends
- Ireland-based cardiovascular drug maker's Q2 net revenue fell 42% yr/yr due to a prior-year licensing payment.
Related News
Comcast Advertising and Clarivoy extend multi-year partnership to deliver deterministic TV & streaming attribution for automotive retailers
CMCSA•
Processa Pharmaceuticals, Inc. Announces Acquisition Of Vidya Therapeutics, Inc. And Approximately $200 Million Concurrent Private Placement To Advance Btk Inhibitor, Vt-7208, In Multiple Disease Areas
PCSA•
